Maria Tolia, Associate Professor at the University of Crete, shared a post on LinkedIn:
“Exploring the Full Potential of SBRT in Advanced Prostate Cancer.
RADIOSA Trial and Beyond
In this presentation, Dr. Giulia Marvaso explores the design, results, and clinical significance of the phase II RADIOSA trial, which compares stereotactic body radiotherapy (SBRT) alone to SBRT combined with a short course of androgen deprivation therapy (ADT) in patients with hormone-sensitive oligo-recurrent prostate cancer. She addresses patient selection, treatment approaches, progression-free survival outcomes, and analyses of translational biomarkers, emphasizing the potential of intensified treatment strategies within a biologically diverse patient population. Professor Jereczek-Fossa discusses the impact of recent and ongoing SBRT trials on the evolving landscape of metastatic prostate cancer treatment. Dr. Mazzola illustrates the practical application of SBRT in daily clinical practice, drawing on real-world case examples to connect research findings with everyday patient care.
Learning Objectives:
- Understand the clinical rationale and trial design of the RADIOSA study, including inclusion criteria and endpoints relevant to oligorecurrent prostate cancer.
- Evaluate the efficacy and toxicity outcomes of SBRT with or without ADT and their implications for routine clinical practice and discuss clinical cases.
- Discuss ongoing SBRT trials, including translational research and future directions for biomarker integration and treatment personalization in oligometastatic prostate cancer.
This webinar is pending approval by CAMPEP for 1 MPCEC hour and approved by ASRT for 1 category A credit.”
More posts featuring Maria Tolia.